Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04648202 · ClinicalTrials.gov registry record · Phase 1
FS120 Phase 1/1b Study in Patients With Advanced Malignancies
A Phase 1 study of Advanced Cancer and Metastatic Cancer, sponsored by invoX Pharma Limited.
- Active
- Registry status
- Phase 1
- Development phase
- 82
- Enrollment target
- 9
- Study locations
NCT04648202: Active Phase 1 study of Advanced Cancer and Metastatic Cancer, sponsored by invoX Pharma Limited.
NCT04648202 is a Phase 1 study of Advanced Cancer and Metastatic Cancer that is active but no longer recruiting, run by invoX Pharma Limited. The registered enrollment target is 82 participants, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (67% lower). The trial reports 9 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04648202, a Phase 1 study of Advanced Cancer and Metastatic Cancer, is active but no longer recruiting, sponsored by invoX Pharma Limited.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 82 participants
- Enrollment target
- 9
- Study locations
Study Summary
This is a Phase 1/1b, multicenter, open label study to evaluate the Safety and Antitumor Activity of FS120, an OX40/CD137 Bispecific Antibody, Alone and in Combination with Pembrolizumab, in Subjects with Advanced Malignancies
Primary Outcome
Safety and tolerability will be evaluated by collection of AEs, SAEs and DLTs according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0.
Conditions Studied
Interventions
- DRUG FS120
Study Locations (9)
Other
- NEXT Oncology, Hospital Quironsalud Barcelona - Barcelona
- Hospital Universitario Vall d'Hebron - Barcelona
- Hospital Universitario Fundacion Jimenez Diaz - Madrid
- Hospital Universitario 12 de Octubre - Madrid
- Hospital Clinico Universitario de Valencia - Valencia
Texas
- MD Anderson Cancer Center - Houston
- South Texas Accelerated Research Therapeutics (START) - San Antonio
Connecticut
- Yale University - New Haven
Utah
- Huntsman Cancer Institute, University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2020-11-18 |
| Est. Completion | 2026-03-01 |
| Phase | Phase 1 |
What the registry record for NCT04648202 still lists
NCT04648202 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 82 participants, a relatively small participant target, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (67% lower).
The record links to 2 conditions, with Advanced Cancer appearing as the primary indexed condition, and to 1 intervention - of which FS120 is the first listed.
NCT04648202 lists 9 locations in 4 states (Other, Texas, Connecticut).
Frequently Asked Questions
What is clinical trial NCT04648202 about?
NCT04648202 is a clinical study titled "FS120 Phase 1/1b Study in Patients With Advanced Malignancies". This is a Phase 1/1b, multicenter, open label study to evaluate the Safety and Antitumor Activity of FS120, an OX40/CD137 Bispecific Antibody, Alone and in Combination with Pembrolizumab, in Subjects with Advanced Malignancies
What is the current status of trial NCT04648202?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 82 participants. The study started on 2020-11-18. Estimated completion is 2026-03-01.
What conditions does trial NCT04648202 study?
This clinical trial studies the following conditions: Advanced Cancer, Metastatic Cancer.
What interventions are being tested in trial NCT04648202?
The interventions under investigation include: FS120 (DRUG).
Who is sponsoring clinical trial NCT04648202?
This trial is sponsored by invoX Pharma Limited, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04648202 being conducted?
This trial has 9 study locations across Connecticut, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04648202's enrollment target sits among peer trials
82 66th of 122 higher than 57 of 122 other Advanced Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss
RECRUITING · Phase 1
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study in Patients With Advanced Cancers
RECRUITING · Phase 1
-
A Study of MGC026 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03319901 · 82 participants · Phase 1
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
- NCT03493425 · 82 participants · Phase 2
Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
- NCT04105270 · 82 participants · Phase 2
RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial
- NCT04428658 · 82 participants · NA
Randomized Trial of Supplemental Synchronous and Asynchronous Telehealth to Improve Glycemic Control for Pediatric Patients With Type 1 Diabetes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI